Kits and Methods for Assessing Antioxidant Requirement of a Human

• US 20140315193A1
• Filed: 11/25/2013
• Published: 10/23/2014
• Est. Priority Date: 03/28/2005
• Status: Abandoned Application

• Current Assignee: Genelink Biosciences Incorporated
• Original Assignee: GeneLink, Inc.
• Inventors: DePhillipo, John R., Ricciardi, Robert P.
• Application Number:
  US14/089,416
• Publication Number:
  US 20140315193A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The invention relates to kits and methods for assessing the desirability of supplementing the diet of a human with reduced coenzyme Q (CoQH₂). The methods involve assessing occurrence in the human'"'"'s genome of the NQO1*2 polymorphism of the NQO1 gene. Occurrence of a copy of the polymorphism indicates that the human can benefit from dietary supplementation with CoQH₂, and occurrence of two copies (i.e., homozygosity) of the NQO1*2 polymorphism indicates that dietary supplementation with CoQH₂ can be especially desirable.

Claims

1. A method of assessing the desirability of supplementing the diet of a human with reduced coenzyme Q (CoQH₂), the method comprising assessing occurrence in the human'"'"'s genome of the NQO1*2 polymorphism or a null NQO1 polymorphism, whereby occurrence of a copy of the NQO1*2 polymorphism or the null polymorphism is an indication that it is more desirable to supplement the human'"'"'s diet with CoQH₂ than that of a human whose genome does not comprise the polymorphism.

2. The method of claim 1, further comprising a suitable dosage of CoQH₂ for supplementation of the human'"'"'s diet.

3. The method of claim 2, wherein the suitable dosage is substantially no CoQH₂ if the human'"'"'s genome does not comprise the NQO1*2 polymorphism.

4. The method of claim 2, wherein the suitable dosage is at least about 50 milligrams per day of CoQH₂ if the human'"'"'s genome comprises one copy of the NQO1*2 polymorphism.

5. The method of claim 2, wherein the suitable dosage is at least about 500 milligrams per day of CoQH₂ if the human'"'"'s genome comprises two copies of the NQO1*2 polymorphism.

6. The method of claim 1, wherein occurrence of the NQO1*2 polymorphism is assessed by contacting a nucleic acid derived from the human'"'"'s genome with a first oligonucleotide that anneals with higher stringency with the NQO1*2 polymorphism than with the NQO1*1 form of the NQO1 gene and assessing annealing of the first oligonucleotide and the nucleic acid, whereby annealing of the first oligonucleotide and the nucleic acid is an indication that the human'"'"'s genome comprises the NQO1*2 polymorphism.

7. The method of claim 6, wherein the first oligonucleotide is attached to a support.

8. The method of claim 6, wherein the first oligonucleotide is a molecular beacon oligonucleotide.

9. The method of claim 6, wherein occurrence of the NQO1*2 polymorphism is further assessed by contacting the nucleic acid with a second oligonucleotide that anneals with higher stringency with the NQO1*1 form of the NQO1 gene than with the NQO1*2 polymorphism and assessing annealing of the second oligonucleotide and the nucleic acid, whereby annealing of the second oligonucleotide and the nucleic acid is an indication that at least one allele of the NQO1 gene in the human'"'"'s genome does not comprise the NQO1*2 polymorphism.

10. The method of claim 9, wherein the second oligonucleotide is attached to a support.

11. The method of claim 10, wherein the first and second oligonucleotides are attached to the same support.

12. The method of claim 9, wherein the second oligonucleotide is a molecular beacon oligonucleotide.

13. The method of claim 12, wherein the first and second oligonucleotides are spectrally distinct molecular beacon oligonucleotides.

19. The method of claim 1, wherein the null polymorphism is NQO1*2.

20. The method of claim 1, wherein the null polymorphism is NQO1*3.

14. A method of formulating a coenzyme Q- (CoQ-)containing antioxidant composition for administration to a human, the method comprising assessing occurrence in the human'"'"'s genome of the NQO1*2 polymorphism and including CoQH₂ in the composition if the polymorphism occurs in the genome.

15. The method of claim 14, further comprising formulating the composition so that substantially all of the CoQ is in the form of CoQH₂ if the human is homozygous for the polymorphism.

16. A method of assessing the advisability that a human should employ a dietary supplement comprising CoQH₂, the method comprising assessing occurrence in the human'"'"'s genome of the NQO1*2 polymorphism, whereby occurrence of a copy of the polymorphism or homozygosity of the human for the polymorphism is an indication that the human should employ a dietary supplement comprising CoQH₂.

17. (canceled)

18. (canceled)